GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Excelsior Biopharma Inc (ROCO:6496) » Definitions » EV-to-Revenue

Excelsior Biopharma (ROCO:6496) EV-to-Revenue : 1.57 (As of Jun. 02, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Excelsior Biopharma EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Excelsior Biopharma's enterprise value is NT$1,383.7 Mil. Excelsior Biopharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was NT$881.7 Mil. Therefore, Excelsior Biopharma's EV-to-Revenue for today is 1.57.

The historical rank and industry rank for Excelsior Biopharma's EV-to-Revenue or its related term are showing as below:

ROCO:6496' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.39   Med: 1.05   Max: 4.99
Current: 1.57

During the past 13 years, the highest EV-to-Revenue of Excelsior Biopharma was 4.99. The lowest was 0.39. And the median was 1.05.

ROCO:6496's EV-to-Revenue is ranked better than
65.47% of 973 companies
in the Drug Manufacturers industry
Industry Median: 2.43 vs ROCO:6496: 1.57

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-02), Excelsior Biopharma's stock price is NT$24.50. Excelsior Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was NT$19.07. Therefore, Excelsior Biopharma's PS Ratio for today is 1.28.


Excelsior Biopharma EV-to-Revenue Historical Data

The historical data trend for Excelsior Biopharma's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Excelsior Biopharma EV-to-Revenue Chart

Excelsior Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.43 0.47 0.84 1.48 1.84

Excelsior Biopharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.66 1.96 1.87 1.84 1.70

Competitive Comparison of Excelsior Biopharma's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Excelsior Biopharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Excelsior Biopharma's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Excelsior Biopharma's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Excelsior Biopharma's EV-to-Revenue falls into.


;
;

Excelsior Biopharma EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Excelsior Biopharma's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1383.744/881.705
=1.57

Excelsior Biopharma's current Enterprise Value is NT$1,383.7 Mil.
Excelsior Biopharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$881.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Excelsior Biopharma  (ROCO:6496) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Excelsior Biopharma's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=24.50/19.069
=1.28

Excelsior Biopharma's share price for today is NT$24.50.
Excelsior Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$19.07.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Excelsior Biopharma EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Excelsior Biopharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Excelsior Biopharma Business Description

Traded in Other Exchanges
N/A
Address
Zhongxiao E. Road, 5Floor, No.508, Sector 7, Nangang District, Taipei, TWN, 11561
Excelsior Biopharma Inc is mainly engaged in western medicines, importing and exporting of Active Pharmaceutical Ingredients, food, cosmecteuticals and development of cosmetics, research, importing, and exporting of technologies, pharmaceutical technologies transfer and cooperative development and improvement. Geographically, it derives revenue from Taiwan, China and others, with majority of revenue earned from Taiwan.

Excelsior Biopharma Headlines

No Headlines